Stockscreener 앱 받기
10.40
11.71%
1.19
전일 마감가:
$9.21
열려 있는:
$9.38
하루 거래량:
6.26M
Relative Volume:
1.33
시가총액:
$1.71B
수익:
$1.12B
순이익/손실:
$440.30M
주가수익비율:
4.3688
EPS:
2.3805
순현금흐름:
$-251.02M
1주 성능:
+15.60%
1개월 성능:
+25.17%
6개월 성능:
+48.04%
1년 성능:
+41.91%
1일 변동 폭
$9.38
$10.52
1주일 범위
$8.92
$10.52
52주 변동 폭
$6.13
$11.97
노바백스 Stock (NVAX) Company Profile
명칭
Novavax Inc
전화
240-268-2000
주소
21 FIRSTFIELD RD, GAITHERSBURG, MD
Compare NVAX vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
10.39 | 1.51B | 1.12B | 440.30M | -251.02M | 2.3805 |
VRTX
Vertex Pharmaceuticals Inc
|
436.73 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
636.45 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
809.33 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
296.56 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
153.84 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
노바백스 Stock (NVAX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-10-24 | 재개 | Cantor Fitzgerald | Overweight |
| 2025-08-28 | 재개 | H.C. Wainwright | Buy |
| 2025-08-20 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-06-17 | 개시 | Citigroup | Sell |
| 2025-02-28 | 개시 | BTIG Research | Buy |
| 2024-07-30 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2024-05-10 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2024-05-10 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2023-08-09 | 업그레이드 | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | 다운그레이드 | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | 재확인 | B. Riley Securities | Buy |
| 2022-12-30 | 재확인 | H.C. Wainwright | Buy |
| 2022-12-02 | 개시 | Jefferies | Hold |
| 2022-09-22 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2022-05-20 | 개시 | BofA Securities | Underperform |
| 2022-02-23 | 재확인 | B. Riley Securities | Buy |
| 2022-02-22 | 재개 | Jefferies | Buy |
| 2022-01-21 | 개시 | Cowen | Outperform |
| 2021-05-12 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-12-14 | 개시 | Jefferies | Buy |
| 2020-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2020-08-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2020-08-05 | 다운그레이드 | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-07-08 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | 재확인 | B. Riley FBR | Buy |
| 2020-06-29 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-05-28 | 재확인 | B. Riley FBR | Buy |
| 2020-05-12 | 재확인 | H.C. Wainwright | Buy |
| 2020-04-30 | 재확인 | H.C. Wainwright | Buy |
| 2019-11-27 | 재개 | B. Riley FBR | Buy |
| 2019-08-14 | 재확인 | H.C. Wainwright | Buy |
| 2019-02-28 | 다운그레이드 | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | 개시 | Ladenburg Thalmann | Buy |
| 2018-12-11 | 개시 | Oppenheimer | Outperform |
| 2018-11-26 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | 업그레이드 | JP Morgan | Underweight → Overweight |
| 2018-03-29 | 업그레이드 | Seaport Global Securities | Neutral → Buy |
모두보기
노바백스 주식(NVAX)의 최신 뉴스
US FDA advisers to weigh updating 2026-27 COVID vaccines to target XFG variant - Reuters
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
3 Reasons NVAX is Risky and 1 Stock to Buy Instead - Yahoo Finance
Operating margin % of Novavax, Inc. – BSESOF:NVV1 - TradingView
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
NVAX News | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
NVAX Stock Price, Quote & Chart | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
Small-Cap Stocks to Avoid: Peloton, Novavax, and BKV Face Financial RisksNews and Statistics - IndexBox
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Why (NVAX) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Assessing Novavax (NVAX) Valuation As Trading Swings Revive Investor Interest - Yahoo Finance
Novavax Inc stock (US66987V1098): earnings volatility and Covid-vaccine hopes in focus - AD HOC NEWS
Novavax, Inc. Trade Ideas — BOATS:NVAX - TradingView
Novavax Inc stock (US6707721049): vaccine specialist in focus after latest COVID shot update - AD HOC NEWS
GoodRx, RadNet, Addus HomeCare, Novavax, and Mettler-Toledo Shares Plummet, What You Need To Know - Yahoo Finance
The Top 5 Analyst Questions From Novavax’s Q1 Earnings Call - Yahoo Finance
Novavax stock (US66987V1098): vaccine maker faces fresh focus after recent company updates - AD HOC NEWS
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
Novavax COVID-19 Vaccine Approved In Japan, Triggers Milestone Payment From Partner Takeda - MSN
Shah Capital Management will vote 'No' across five proposals on Novavax's June 18 ballotSEC filing - marketscreener.com
Shah Capital Management Will Vote ‘No' Across Five Proposals On Novavax's June 18 BallotSEC Filing - TradingView
Shah Capital holds 9% Novavax stake and challenges board (NVAX) - Stock Titan
Shah Capital Management Sent a Presentation to the Board of Novavax, Inc - marketscreener.com
Novavax, Inc. (NVAX) is attracting investor attention: Here is what you should know - MSN
Novavax stock (US66987V1098): Latest developments and business update - AD HOC NEWS
Novavax targets $230M-$270M 2026 adjusted revenue while refining 2028 opex to $150M-$200M - MSN
NVAX Technical Analysis | Trend, Signals & Chart Patterns | NOVAVAX INC (NASDAQ:NVAX) - ChartMill
3 Small-Cap Stocks That Fall Short - The Globe and Mail
NVAX stock eyes breakout week: Novavax claims patients were ‘twice as likely’ to pick its COVID shot over Moderna again - MSN
Transcript : Novavax, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-13-2026 03 - marketscreener.com
NVAX: Pivot to a platform model and Matrix-M partnerships drive growth, targeting profitability by 2028 - TradingView
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Q1 2026 Novavax Inc Earnings Call Transcript - GuruFocus
Novavax Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Novavax Inc at JPMorgan Healthcare Conference Transcript - GuruFocus
Vanguard Group Inc. Has $103.96 Million Position in Novavax, Inc. $NVAX - MarketBeat
Why Novavax (NVAX) Stock Is Trading Up Today - Yahoo Finance
Novavax Inc. stock underperforms Tuesday when compared to competitors despite daily gains - MarketWatch
Novavax (NVAX) Q1 2026 Earnings Transcript - AOL.com
Investors heavily search Novavax, Inc. (NVAX): Here is what you need to know - MSN
Novavax Bets on Turnaround Momentum Following Pfizer Partnership - citybiz
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know - Yahoo Finance
Hantavirus Scare Sparks Vaccine Stock Rally: Moderna, Novavax Climb - Sahm
Novavax: Betting On This Vaccine Maker's Turnaround Story, After Pfizer Deal - Seeking Alpha
TradingKey - TradingKey
Novavax (NVAX) Is Up 25.9% After Pfizer Matrix-M Deal And Q1 Beat On ExpectationsWhat's Changed - Yahoo Finance
Best Biotech Stocks To Follow NowMay 11th - MarketBeat
Moderna Stock Is Up 6% Today: Is It Outperforming Other Vaccine Stocks Like Pfizer and Novavax? - 24/7 Wall St.
Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes - Barchart.com
NVAX Stock Eyes Breakout Week: Novavax Claims Patients Were ‘Twice As Likely’ To Pick Its COVID Shot Over Moderna Again - Stocktwits
노바백스 (NVAX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
노바백스 주식 (NVAX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Newton Charles W. | Director |
Apr 25 '26 |
Option Exercise |
0.00 |
9,520 |
0 |
9,520 |
| Shiver John W. | Director |
Mar 10 '26 |
Option Exercise |
0.00 |
7,947 |
0 |
7,947 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 07 '26 |
Option Exercise |
0.00 |
12,223 |
0 |
136,503 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 03 '26 |
Option Exercise |
0.00 |
43,167 |
0 |
145,130 |
| Jacobs John C | President and CEO |
Mar 03 '26 |
Option Exercise |
0.00 |
150,167 |
0 |
264,130 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
56,334 |
0 |
157,071 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 03 '26 |
Option Exercise |
0.00 |
37,500 |
0 |
101,445 |
| Draghia-Akli Ruxandra | EVP, Research & Development |
Mar 03 '26 |
Option Exercise |
0.00 |
26,667 |
0 |
34,876 |
| Jacobs John C | President and CEO |
Mar 01 '26 |
Option Exercise |
0.00 |
83,333 |
0 |
264,130 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 01 '26 |
Option Exercise |
0.00 |
58,666 |
0 |
130,299 |
2.25%
0.46%
자본화:
|
볼륨(24시간):